Preliminary results from a phase II clinical trial demonstrated similar response rates to T-Dxd treatment between advanced BC patients with HER2 IHC score of 0+ (30.6%) and HER2-low (33.3%) [52]. The gene discussed is ERBB2; the disease is breast cancer.